DR. NATALIA ALEXEEVNA SHCHERBININA MD
Prescription History 1992054589
Internal Medicine - Infectious Disease in Melbourne, FL

NPI Status: Active since August 29, 2012

Contact Information

100 RIALTO PL STE 700
MELBOURNE, FL
ZIP 32901
Phone: (321) 212-9596

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. NATALIA ALEXEEVNA SHCHERBININA MD, an active Infectious Disease specialist practicing in Melbourne, FL. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 116 documented patient claims. Among these therapy options, the most frequently utilized medication is Biktarvy, which accounts for 50 claims alone.

Medication Index


Azithromycin

Generic Formulation: AzithromycinSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 17.0
Days Supply 478
FL State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills50.1
Peer Average Days Supply332
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 72.9% less volume than the regional standard for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $468.31 across this reporting matrix range.

Provider Avg Cost Per Claim

$36.02

State Avg Cost Per Claim

$9.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Biktarvy

Generic Formulation: Bictegrav/Emtricit/Tenofov AlaSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 50
30-Day Fills 50.0
Days Supply 1,500
FL State Average Benchmarks
Peer Average Claims98.0
Peer Average 30-Day Fills100.6
Peer Average Days Supply3,011
Conservative Utilization

This provider writes prescriptions for this formulation 49.0% less frequently than the standard regional baseline metric for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $205,936.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,118.73

State Avg Cost Per Claim

$3,874.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination product is used by itself to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of 3 different drugs: bictegravir, emtricitabine, and tenofovir alafenamide. Bictegravir is called an integrase strand transfer inhibitor-INSTI. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor. Emtricitabine and tenofovir alafenamide are often called NRTIs. Bictegravir/emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Cephalexin

Generic Formulation: CephalexinSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 18.0
Days Supply 416
FL State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills33.4
Peer Average Days Supply301
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 62.5% less volume than the regional standard for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $145.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.08

State Avg Cost Per Claim

$8.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria. This medication will not work for viral infections (such as common cold, flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Ethambutol Hcl

Generic Formulation: Ethambutol HclSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 13.0
Days Supply 390
FL State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills34.5
Peer Average Days Supply1,005
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.0% less volume than the regional standard for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $826.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$75.15

State Avg Cost Per Claim

$62.99

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863)

Therapeutic Applications

Ethambutol is used with other medications to treat tuberculosis (TB). Ethambutol is an antibiotic and works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Rifampin

Generic Formulation: RifampinSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 17
30-Day Fills 21.0
Days Supply 596
FL State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills30.9
Peer Average Days Supply878
Conservative Utilization

This provider writes prescriptions for this formulation 29.2% less frequently than the standard regional baseline metric for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,309.28 across this reporting matrix range.

Provider Avg Cost Per Claim

$77.02

State Avg Cost Per Claim

$64.56

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)

Sulfamethoxazole-Trimethoprim

Generic Formulation: Sulfamethoxazole/TrimethoprimSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 21.0
Days Supply 566
FL State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills31.0
Peer Average Days Supply374
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.6% less volume than the regional standard for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $206.75 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.90

State Avg Cost Per Claim

$5.70

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.

Therapeutic Applications

This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type). This medication should not be used by children less than 2 months of age due to the risk of serious side effects. This medication treats only certain types of infections. It will not work for viral infections (such as flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. NATALIA ALEXEEVNA SHCHERBININA MD provides transparency into local medical care patterns within Melbourne, FL.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Infectious Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.